{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:36:25Z","timestamp":1746318985757},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T00:00:00Z","timestamp":1398643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1245\/s10434-014-3714-6","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T18:35:10Z","timestamp":1398537310000},"page":"3036-3041","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dualistic Classification of Epithelial Ovarian Cancer: Surgical and Survival Outcomes in a Large Retrospective Series"],"prefix":"10.1245","volume":"21","author":[{"given":"Pierluigi Benedetti","family":"Panici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Musella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vertechy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Innocenza","family":"Palaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Perniola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilary","family":"Ruscito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terenzio","family":"Boni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovico","family":"Muzii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,28]]},"reference":[{"key":"3714_CR1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/IGC.0b013e31823c6f80","volume":"22","author":"JD Seidman","year":"2012","unstructured":"Seidman JD, Yemelyanova A, Cosin JA, Smith A, Kurman RJ. Survival rates for International Federation of Gynecology and Obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int J Gynecol Cancer. 2012;22:36\u201371.","journal-title":"Int J Gynecol Cancer."},{"key":"3714_CR2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","volume":"164","author":"Shih IeM","year":"2004","unstructured":"Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511\u20138.","journal-title":"Am J Pathol."},{"key":"3714_CR3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm. Hum Pathol. 2011;42:918\u201331.","journal-title":"Hum Pathol."},{"key":"3714_CR4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433\u201343.","journal-title":"Am J Surg Pathol."},{"key":"3714_CR5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/modpathol.2011.211","volume":"25","author":"JN McAlpine","year":"2012","unstructured":"McAlpine JN, Porter H, Kobel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25:740\u201350.","journal-title":"Mod Pathol."},{"key":"3714_CR6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0020-7292(06)60033-7","volume":"1","author":"AP Heintz","year":"2006","unstructured":"Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006; Suppl 1:S161\u2013S192.","journal-title":"Int J Gynaecol Obstet."},{"key":"3714_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-200001000-00003","volume":"19","author":"SG Silverberg","year":"2000","unstructured":"Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19:7\u201315.","journal-title":"Int J Gynecol Pathol."},{"key":"3714_CR8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1245\/s10434-006-9273-8","volume":"14","author":"P Benedetti Panici","year":"2007","unstructured":"BenedettiPanici P, DeVivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14:1136\u201342.","journal-title":"Ann Surg Oncol."},{"key":"3714_CR9","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/bjc.2011.455","volume":"105","author":"EI Braicu","year":"2011","unstructured":"Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. Br J Cancer. 2011;105:1818\u201324.","journal-title":"Br J Cancer."},{"key":"3714_CR10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.09.023","volume":"48","author":"A Bamias","year":"2012","unstructured":"Bamias A, Sotiropoulou M, Zagouri F, et al. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel\/carboplatin chemotherapy: cell type is the most useful prognostic factor. Eur J Cancer. 2012;48:1476\u201383.","journal-title":"Eur J Cancer."},{"key":"3714_CR11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","volume":"16","author":"R Vang","year":"2009","unstructured":"Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16:267\u201382.","journal-title":"Adv Anat Pathol."},{"issue":"Suppl 2","key":"3714_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/modpathol.3800306","volume":"18","author":"DA Bell","year":"2005","unstructured":"Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(Suppl 2):19\u201332.","journal-title":"Mod Pathol."},{"key":"3714_CR13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/IGC.0b013e31828f7a24","volume":"23","author":"X Chen","year":"2013","unstructured":"Chen X, Zhang J, Cheng W, et al. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23:815\u201322.","journal-title":"Int J Gynecol Cancer."},{"key":"3714_CR14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/IGC.0b013e3182540145","volume":"22","author":"H Kajiyama","year":"2012","unstructured":"Kajiyama H, Shibata K, Mizuno M, et al. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer. 2012;22:801\u20136.","journal-title":"Int J Gynecol Cancer."},{"key":"3714_CR15","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/IGC.0b013e31823eed2c","volume":"22","author":"H Kajiyama","year":"2012","unstructured":"Kajiyama H, Shibata K, Mizuno M, et al. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type? Int J Gynecol Cancer. 2012;22:394\u20139.","journal-title":"Int J Gynecol Cancer."},{"issue":"1","key":"3714_CR16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10147-013-0522-0","volume":"19","author":"H Kajiyama","year":"2014","unstructured":"Kajiyama H, Mizuno M, Shibata K, Kawai M, Nagasaka T, Kikkawa F. Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer. Int J Clin Oncol. 2014; 19(1):121\u2013126","journal-title":"Int J Clin Oncol."},{"key":"3714_CR17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","volume":"114","author":"DM Gershenson","year":"2009","unstructured":"Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114:48\u201352.","journal-title":"Gynecol Oncol."},{"issue":"8","key":"3714_CR18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2407-8-252","volume":"1","author":"S Pignata","year":"2008","unstructured":"Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6\u00a0months: results from the SOCRATES retrospective study. BMC Cancer. 2008;1;8:252.","journal-title":"BMC Cancer."},{"key":"3714_CR19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, et al European Organization for Research and Treatment of Cancer\u2013Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943\u201353.","journal-title":"N Engl J Med."},{"key":"3714_CR20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","volume":"125","author":"SJ Chang","year":"2012","unstructured":"Chang SJ, Bristow RE. Evolution of surgical treatment paradigmsfor advanced-stage ovarian cancer: redefining \u201coptimal\u201d residual disease. Gynecol Oncol. 2012;125:483\u201392.","journal-title":"Gynecol Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3714-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-014-3714-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3714-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T07:24:24Z","timestamp":1559633064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-014-3714-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,28]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["3714"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-3714-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,28]]}}}